Quantcast

Latest Antisense therapy Stories

2014-07-02 08:26:15

CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline. We look forward to continuing to advance...

2014-06-17 08:28:25

CARLSBAD, Calif., June 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis'...

2014-06-12 08:28:34

CARLSBAD, Calif., June 12, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 Wells Fargo Healthcare Conference at 1:10 p.m. ET and participate in the Gene Manipulation Panel at 2:20 p.m. ET on Tuesday, June 17, 2014 in Boston, MA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentations will be available on the "Investors...

2014-06-10 08:29:31

Successful collaboration with AstraZeneca includes two novel cancer drugs in clinical development CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-AR(Rx) in patients with cancer. Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-AR(Rx). ISIS-AR(Rx) is an antisense drug designed to treat patients with prostate cancer by...

2014-06-09 08:28:10

Isis Earns $14 Million Milestone Payment from Biogen Idec CARLSBAD, Calif., June 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-DMPK(Rx). Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement. ISIS-DMPK(Rx) is designed to reduce the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of...

2014-06-04 08:30:11

CARLSBAD, Calif., June 4, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 35(th) Annual Global Healthcare Conference on Wednesday, June 11, 2014 at 8:40 a.m. PT in Rancho Palos Verdes, CA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the...

2014-06-03 08:31:23

CARLSBAD, Calif., June 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2014 Annual Meeting of Stockholders and Open House on Tuesday, June 10 at 2:10 p.m. Pacific Time in Carlsbad, CA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO The agenda for the meeting is as follows:2:00 p.m. - 2:10 p.m. Annual Meeting of...

2014-05-15 08:31:23

CARLSBAD, Calif., May 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "We have had a very productive alliance with GlaxoSmithKline, from which we have advanced three antisense drugs in our...

2014-05-13 16:29:02

CARLSBAD, Calif., May 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 8:00 a.m. ET in New York, NY. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com....

2014-05-08 08:32:07

CARLSBAD, Calif., May 8, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 at 11:20 a.m. PT in Las Vegas, NV. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.